Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $560000.0.

  • Viridian Therapeutics, Inc.\DE's Interest Expenses rose 586.01% to $560000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 1510.08%. This contributed to the annual value of $3.0 million for FY2024, which is 6491.61% up from last year.
  • Viridian Therapeutics, Inc.\DE's Interest Expenses amounted to $560000.0 in Q3 2025, which was up 586.01% from $514000.0 recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Interest Expenses registered a high of $1.4 million during Q4 2024, and its lowest value of $3000.0 during Q4 2021.
  • Its 5-year average for Interest Expenses is $471666.7, with a median of $529000.0 in 2024.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Interest Expenses crashed by 9833.33% in 2021 and then skyrocketed by 550000.0% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Interest Expenses (Quarter) stood at $3000.0 in 2021, then soared by 5500.0% to $168000.0 in 2022, then soared by 445.24% to $916000.0 in 2023, then surged by 49.13% to $1.4 million in 2024, then tumbled by 59.0% to $560000.0 in 2025.
  • Its last three reported values are $560000.0 in Q3 2025, $514000.0 for Q2 2025, and $586000.0 during Q1 2025.